Lupin Pharma Canada Ltd
Lupin Pharma Canada Ltd is the Canadian subsidiary of India's Lupin Limited, established in 2014 and headquartered in Quebec. It commercializes branded specialty products (ZAXINE, Relistor, INTRAROSA), generics, and a biosimilar across gastroenterology, palliative care, and women's health for Canadian healthcare professionals and patients.
- Company typePrivate
- Founded2014
- HeadquartersLongueuil, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lupin Pharma Canada Ltd does
Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, a top-three Indian pharmaceutical group headquartered in Mumbai and founded in 1968. Established in 2014 and headquartered in Longueuil, Quebec with a regional office in Mississauga, Ontario, the Canadian operation employs 37 staff and serves Canadian patients and healthcare professionals across three therapeutic franchises: Gastroenterology, Palliative Care, and Respiratory/Women's Health.
The company markets a differentiated mix of branded specialty products, generics, and a biosimilar. The branded portfolio centers on three in-licensed assets: ZAXINE® (rifaximin 550mg) for hepatic encephalopathy and IBS-D, Relistor® (methylnaltrexone) for opioid-induced constipation, and INTRAROSA® (prasterone 6.5mg vaginal ovule) for postmenopausal vulvovaginal atrophy. The generic portfolio spans cardiovascular (propranolol), anti-infectives (cephalexin, letermovir), respiratory (tiotropium), antiallergics (sodium cromoglicate) and women's health products (oral contraceptives, estradiol). The biosimilar line includes RYMTI® (etanercept) for autoimmune disease. All products are produced, researched or licensed through the parent company's 15 manufacturing sites and 7 research centres.
Lupin Pharma Canada generates revenue primarily through B2B wholesale distribution to Canadian pharmacies and distributors at standard net-30 payment terms with a $2,500 minimum direct-order value, and through licensing/royalty streams tied to its distribution and commercialization agreements with partners such as Salix Pharmaceuticals and Endoceutics. Go-to-market is field-sales-led, targeting gastroenterologists, palliative care specialists, respiratory physicians and women's health prescribers via a dedicated HCP portal, professional community, and the Lupin Genesis patient assistance program. Its products are labelled exclusively for the Canadian market with export prohibited.
Lupin Pharma Canada Ltd firmographics
Firmographics- Name
- Lupin Pharma Canada Ltd
- Legal name
- Lupin Pharma Canada Ltd
- Website
- https://lupinpharma.ca
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lupin Pharma Canada Ltd is the Canadian subsidiary of India's Lupin Limited, established in 2014 and headquartered in Quebec. It commercializes branded specialty products (ZAXINE, Relistor, INTRAROSA), generics, and a biosimilar across gastroenterology, palliative care, and women's health for Canadian healthcare professionals and patients.
- Ownership category
- akta.pro rank
Lupin Pharma Canada Ltd industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD), Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)
Keywords
Where Lupin Pharma Canada Ltd is headquartered
LocationHeadquarters
- HQ city
- Longueuil
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
Lupin Pharma Canada Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Others
Revenue model
- Branded Pharmaceutical Sales: Revenue generated from the sale of branded prescription medicines including INTRAROSA, Relistor, and Zaxine to healthcare providers and patients across Canada. Products are distributed through wholesale channels and direct pharmacy fulfillment.
- Generic Pharmaceutical Sales: Revenue from generic pharmaceutical products including LUPIN-PROPRANOLOL, LUPIN-CEPHALEXIN, LUPIN-LETERMOVIR, NALCROM, and others distributed through standard pharmaceutical supply chains.
- Licensing and Distribution Partnerships: Revenue through licensing and distribution agreements with partners such as Salix Pharmaceuticals for exclusive Canadian rights to gastroenterology products, and Endoceutics for INTRAROSA commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B pharmaceutical wholesale pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Lupin Pharma Canada Ltd product offering
Product offeringCore offering
Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, established in 2014 and headquartered in Toronto with operations in Montreal. The company markets and distributes a portfolio of branded, generic, and biosimilar prescription pharmaceuticals across four therapeutic franchises — Gastroenterology, Palliative Care, Respiratory, and Women's Health — to Canadian patients through wholesale distribution partners and a dedicated patient support program.
Product overview
Lupin Pharma Canada Ltd operates as the Canadian subsidiary of Lupin Limited, offering a diversified portfolio of branded and generic pharmaceutical products. The branded portfolio includes three key innovative products: INTRAROSA® (prasterone vaginal ovule for women's health), ZAXINE® (rifaximin for GI conditions), and Relistor® (methylnaltrexone for opioid-induced constipation). The generic portfolio includes antibiotics (LUPIN-CEPHALEXIN), cardiovascular medications (LUPIN-PROPRANOLOL), respiratory treatments (Lupin-Tiotropium), women's health products (Lupin-Estradiol, JENCYCLA, LAYLAA), antiallergics (NALCROM), antivirals (LUPIN-LETERMOVIR), and others. The biosimilar portfolio includes RYMTI® (etanercept). The company also operates the LUPIN Genesis Patient Support Program for patient assistance. The company focuses on three key therapeutic areas: Gastroenterology, Palliative Care, and Respiratory.
Differentiator
Problem solved
Functional benefit
Brands
- LUPIN Genesis Patient Support Program: Patient support program offered by Lupin Pharma Canada
Products and services
- INTRAROSA INTRAROSA is a prescription pharmaceutical product commercialized by Lupin Pharma Canada in the Women's Health therapeutic franchise; it is supplied to Canadian pharmacies via wholesale partners for prescribing physicians and their patients.
- ZAXINE ZAXINE is a branded prescription pharmaceutical marketed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distributors.
- Relistor Relistor is a branded prescription pharmaceutical distributed by Lupin Pharma Canada in Canada; it is sold to Canadian pharmacies through wholesale partners for prescribing physicians and patients.
- RYMTI RYMTI is a biosimilar prescription pharmaceutical marketed and distributed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distribution partners.
- Generic pharmaceutical portfolio A portfolio of generic prescription pharmaceuticals sold by Lupin Pharma Canada across its Gastroenterology, Palliative Care, Respiratory, and Women's Health franchises; distributed to Canadian pharmacies through wholesale partners.
- LUPIN Genesis Patient Support Program LUPIN Genesis is Lupin Pharma Canada's patient support program that assists Canadian patients and prescribers with access, coverage navigation, and adherence for the company's specialty pharmaceutical products.
Quantifiable outcome
- INTRAROSA demonstrated statistically significant beneficial effects (p=0.017 to < 0.0001) at 2 weeks on pH and cell composition, with 52% to 81% of 12-week effects observed by 2 weeks
- +1 more outcomes
Companies that use Lupin Pharma Canada Ltd
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Lupin Pharma Canada Ltd technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lupin Pharma Canada Ltd partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- EndoceuticscoreLupin Pharma Canada partnered with Endoceutics to commercialize INTRAROSA (prasterone 6.5mg vaginal ovule) for treatment of postmenopausal vulvovaginal atrophy in Canada. INTRAROSA is Endoceutics' flagship product developed in Quebec, Canada and manufactured in Mont-Saint-Hilaire, Canada. The partnership expands Lupin's women's health portfolio in Canada.
- Salix PharmaceuticalscoreLupin entered into an exclusive distribution agreement with Salix Pharmaceuticals for Canadian rights to Zaxine (rifaximin) 550mg for hepatic encephalopathy and IBS-D, Relistor (methylnaltrexone) subcutaneous injection for opioid-induced constipation, and other gastroenterology products. The agreement grants Lupin exclusive rights to promote, distribute and market these products in Canada.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Lupin Pharma Canada Ltd competitors and assessment
Company assessmentDirect peers
- Knight Therapeutics: Knight Therapeutics is a Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across Canada and select international markets — closely comparable to Lupin Pharma Canada's licensing-driven model.
- Viatris Canada (formerly Mylan): Viatris Canada offers a broad portfolio of generics, branded, and biosimilars across multiple therapeutic areas including gastroenterology, women's health, and respiratory — directly comparable to Lupin's diversified portfolio.
- Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer with a broad generics portfolio spanning antibiotics, cardiovascular, women's health, and CNS — directly competing with Lupin Pharma Canada's generic lineup.
- Sandoz Canada: Sandoz Canada is the generics and biosimilars arm of Novartis, operating one of the broadest generic and biosimilar portfolios in Canada — a direct peer in both the generic and emerging biosimilars space where Lupin competes with RYMTI.
- Salix Pharmaceuticals: Salix (a Bausch Health subsidiary) is the originator partner for ZAXINE and Relistor and grants Lupin exclusive Canadian rights to these gastroenterology and palliative care products. Directly comparable as a U.S.-based specialty pharma company focused on gastroenterology.
- Teva Canada: Teva Canada is one of the largest generic and specialty pharmaceutical companies in Canada, offering both branded and generic products across multiple therapeutic areas including gastroenterology, women's health, and central nervous system — directly overlapping with Lupin's portfolio.
- Pharmascience Inc. Pharmascience is a major Canadian-owned pharmaceutical company offering generics and specialty products across multiple therapeutic categories, competing head-to-head with Lupin in the Canadian market.
- AA Pharma Inc. AA Pharma is a Canadian specialty generic pharmaceutical company focused on niche therapeutic areas, offering a comparable specialty generics approach to Lupin Pharma Canada.
Emerging players
- Endoceutics: Endoceutics is the Canadian women's health biotech that developed and manufactures INTRAROSA — Lupin's partner for Canadian commercialization. Comparable as a Quebec-based specialty pharma company targeting women's health with innovative therapies.
Broad incumbents
- Bausch Health Canada: Bausch Health is the parent of Salix and a broad incumbent in Canadian specialty pharma with established gastroenterology, dermatology, and eye-health franchises — overlapping with Lupin's gastroenterology and specialty focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Lupin Pharma Canada Ltd social profiles
Digital presenceLupin Pharma Canada Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lupin Pharma Canada Ltd leadership team
Management profileNumber of profiles
Profiles2 records
Lupin Pharma Canada Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lupin Pharma Canada Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lupin Pharma Canada Ltd
What does Lupin Pharma Canada Ltd do?
Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, established in 2014 and headquartered in Toronto with operations in Montreal. The company markets and distributes a portfolio of branded, generic, and biosimilar prescription pharmaceuticals across four therapeutic franchises — Gastroenterology, Palliative Care, Respiratory, and Women's Health — to Canadian patients through wholesale distribution partners and a dedicated patient support program.
Is Lupin Pharma Canada Ltd a public or private company?
Lupin Pharma Canada Ltd is a private company. It is classified as public and is currently operating.
When was Lupin Pharma Canada Ltd founded?
Lupin Pharma Canada Ltd was founded in 2014. It employs 11 to 50 people.
Where is Lupin Pharma Canada Ltd based?
Lupin Pharma Canada Ltd is headquartered in Longueuil, Canada, in the North America region.
How does Lupin Pharma Canada Ltd make money?
Three revenue lines are on record. Branded Pharmaceutical Sales are the primary driver. The others are generic Pharmaceutical Sales and licensing and Distribution Partnerships.
Who are Lupin Pharma Canada Ltd's main competitors?
Direct peers on record are Knight Therapeutics, Viatris Canada (formerly Mylan), Apotex Inc., Sandoz Canada, Salix Pharmaceuticals, Teva Canada, Pharmascience Inc. and AA Pharma Inc.. Endoceutics is listed as an emerging player. Bausch Health Canada is listed as a broad incumbent.
Does Lupin Pharma Canada Ltd have an API?
No public API is recorded for Lupin Pharma Canada Ltd.
What industry is Lupin Pharma Canada Ltd in?
Lupin Pharma Canada Ltd's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 5122.